Santen Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan, hereinafter Santen) and jCyte Inc. (Headquarters: Newport, California, US, hereinafter jCyte) announced the conclusion of an exclusive licensing contract covering the development, registration and commercialization rights in Japan, Asia and Europe to jCell, a first-in-class investigational therapy, currently in clinical development for retinitis pigmentosa.
jCyte has been developing a treatment for retinitis pigmentosa, a genetic degenerative retinal condition. jCell is a cell therapy product, and its principal component is retinal progenitor cells. The product is administered through intravitreal injection, a procedure that is minimally invasive in comparison to the standard method of direct retinal injection used for other genetic and cell therapies. The cells introduced into the eye release cell growth and protection factors that activate and protect retinal cells. Such mechanism of action is believed to have the potential to be applied to all types of retinitis pigmentosa, irrespective of the condition's genetic causes. Plans are also in place to investigate the potential application of jCell to degenerative diseases affecting retinal cells other than retinitis pigmentosa.
In the US, the evaluable portion of a Phase 2b clinical trial of jCell for the treatment of retinitis pigmentosa has been completed, and the crossover portion continues. jCell therapy has been administered in over 100 patients. The US Food and Drug Administration (FDA) has granted jCyte Regenerative Medicine Advanced Therapy (RMAT) designation based on early clinical data, making jCell potentially eligible for biologics license application priority review. In addition to RMAT, jCell has received orphan drug designation from the FDA and the European Medicines Agency (EMA).
Under the terms of the licensing agreement, jCyte will receive up to $252 million in upfront and milestone payments during the course of the collaboration, not including future royalties on jCell net sales outside of the United States in Europe, Asia and Japan. jCyte will receive an upfront fee of $50 million in cash, $12 million in a convertible note offering, and up to an additional $190 million in cash milestone payments, based on regulatory approval and initial sales in Japan, and certain markets in Asia and Europe. jCyte is also entitled to receive royalty payments on net sales of investigational therapy jCell in Europe, Asia and Japan.
For healthcare professional media
Retinitis pigmentosa, a disease caused by genetic mutations, causes wide-ranging degeneration of retinal photoreceptor cells and retinal pigment epithelial cells. Characteristic symptoms caused by the condition include night blindness, narrowing of the visual field, and decreased visual acuity. It often strikes people in their teens, with many patients rendered blind by middle age. Worldwide, approximately 1.9 million patients suffer from the disease. Retinitis pigmentosa has a wide impact on everyday life as it affects any operation requiring vision, including movement and learning. Unmet medical needs in relation to retinitis pigmentosa are significant and treatments that are currently available do not provide an underlying cure or reduction in the speed of retinal degeneration.
Santen is committed to major investments in innovative new treatments that will enable us to provide wider treatment choice for patients, fulfilling our mission to contribute further to patients' lives.
Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment